Phase IIa Open Label, Randomized Clinical Trial to Study Vintafolide and Paclitaxel in Subjects with Advanced Triple Negative Breast Cancer Using SPECT/CT scan with Etarfolatide (EC20) for Subject Selection Ensayo clínico de fase IIa abierto y aleatorizado para estudiar Vintafolide y paclitaxel en pacientes con cáncer de mama triplemente negativo avanzado, con selección de pacientes mediante etarfolatide (EC20) To evaluate the progression-free survival of vintafolide monotherapy relative to paclitaxel and the progression-free survival of vintafolide + paclitaxel combination therapy relative to paclitaxel in...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of CANCIDAS in Children types of ungal infections The main objectives of this study are to evaluate the safety, tolerability, and efficacy of caspofungin therapy, administered as 50 mg/m2 IV once daily (maximum 70 mg/day) following a loading dose of ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III, Randomized, Double-blind Study to Evaluate Chemotherapy plus Pembrolizumab vs Chemotherapy plus Placebo as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) 1. To evaluate the rate of pCR using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) as assessed by the local pathologist at the ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical research study to test the safety/tolerability and effectiveness of an investigational study medication (subcutaneous SCH 900222/MK-3222) in improving the signs and symptoms of moderate-to-severe chronic plaque psoriasis, and to compare it to an approved medication for the treatment of psoriasis called etanercept Primary Efficacy Objective: To assess the efficacy of SCH 900222/MK-3222, hereafter referred to as MK-3222, compared to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measu...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Oral MK8669 in Children/Adolescents with Solid Tumors (6-17 years) • To identify the dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ridaforolimus when administered to children from 6 to less than 18 years of age with advanced solid tumours. • To...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of Boceprevir in Patients who have HIV and Hepatitis C The primary objective of this study is to compare the efficacy of boceprevir (PO) in combination with peginterferon alfa-2b (PEG2b) (SC) plus ribavirin weight-based dosing (WBD) PO to therapy with PEG...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with Dyslipidemia Main objective: Assess the effects of ERN/LRPT relative to ERN on flushing during the post-withdrawal dosing period as measured by number of days/week with GFSS >4 during weeks 21 to 32.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

sitagliptin +simvastatin coadministration safety study sitagliptin és simvastatin egyidejű alkalmazásának biztonságossági vizsgálata 1. To assess the effect of MK-0431D compared to sitagliptin alone on A1C. 2. To assess the safety and tolerability of MK-0431D.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase III study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab in first line metastatic squamous NSCLC. Estudio de fase III de carboplatino y paclitaxel o paclitaxel unido a albúmina en nanopartículas (nab-paclitaxel), con o sin pembrolizumab, en el CPNM epidermoide y metastásico en primera línea de tratamiento In subjects with metastatic squamous non-small cell lung cancer (NSCLC) receiving investigator’s choice of standard of care chemotherapy (i.e. carboplatin and a taxane): 1. To evaluate progression fre...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Two Year Study to Assess the Efficacy, Safety, and Tolerability of MK-0364 in Obese Patients Followed by a 1-Year Extension In obese patients, (1) to assess the effects of 2 or 4 mg MK-0364 after 1 year of treatment on body weight; (2) to assess the safety and tolerability of MK-0364 during base and extension studies.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune